Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure

Pharmacotherapy

Volumn 26, Issue 1, 2006, Pages 34-43

  Gerhard, Tobias ^a   Zineh, Issam ^a,b   Winterstein, Almut G ^a   Hartzema, Abraham G ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Cost effectiveness; Dobutamine; Heart failure; Nesiritide; Outcomes; Pharmacoeconomics

Indexed keywords

DOBUTAMINE; NESIRITIDE;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; HEART FAILURE; HOSPITAL ADMISSION; HUMAN; MODEL; MONTE CARLO METHOD; MORTALITY; PROBABILITY; TREATMENT OUTCOME;

CARDIOTONIC AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; DOBUTAMINE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; MODELS, STATISTICAL; MONTE CARLO METHOD; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN;

EID: 30544435059     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2006.26.1.34     Document Type: Article

References (38)

1. Hoffman JM, Shah ND, Vermeulen LC, Hunkler RJ, Hontz KM. Projecting future drug expenditures-2004. Am J Health-Syst Pharm 2004;61:145-58.
2. NDCHealth, Atlanta, GA. NDCHealth top 200 drugs for 2003 by U.S. sales. Available from http://www.ndchealth.com/press_ center/uspharmaindustrydata/ top200drugs_03.htm. Accessed July 6, 2005.
3. NDC Health, Atlanta, GA. NDCHealth top 200 drugs for 2004 by U.S. sales. Available from http://www.ndchealth.com/press_center/uspharmaindustrydata/ ndchealthtop2002004sales. htm. Accessed July 6, 2005.
4. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003;362:316-22.
5. Lewis DA, Gurram NR, Abraham WT, Akers WS. Effect of nesiritide versus milrinone in the treatment of acute decompensated heart failure. Am J Health-Syst Pharm 2003;60(suppl 4):S16-20.
6. McBride BF, White CM. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. Pharmacotherapy 2003;23:997-1020.
7. Noviasky JA, Kelberman M, Whalen KM, Guharoy R, Darko W. Science or fiction: use of nesiritide as a first-line agent? Pharmacotherapy 2003;23:1081-3.
8. Peacock WF. Clinical and economic impact of nesiritide. Am J Health-Syst Pharm 2003;60(suppl 4):S21-6.
9. Zineh I, Schofield RS, Johnson JA. The evolving role of nesiritide in advanced or decompensated heart failure. Pharmacotherapy 2003;23:1266-80.
10. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide study group. N Engl J Med 2000;343:246-53.
11. [Errata in N Engl J Med 2000;343:1504
12. and N Engl J Med 2000;343:896.]
13. Burger AJ, Horton DP, LeJemtel T, et al, for the Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J 2002;144:1102-8.
14. Colucci WS. Nesiritide for the treatment of decompensated heart failure. J Card Fail 2001;7:92-100.
15. Emerman CL. Safety and efficacy of nesiritide for the treatment of decompensated heart failure. Rev Cardiovasc Med 2002;3(suppl 4):S28-34.
16. Keating GM, Goa KL. Nesiritide: a review of its use in acute decompensated heart failure. Drugs 2003;63:47-70.
17. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004;29:707-69.
18. Stiver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798-803.
19. Silver MA, Maisel A, Yancy CW, et al. BNP consensus panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004;10:1-30.
20. [Erratum in Congest Heart Fail 2005;11:102.]
21. Wylie JV, Tsao L. Nesiritide for the treatment of decompensated heart failure. Expert Rev Cardiovasc Ther 2004;2:803-13.
22. Sharma M, Teerlink JR. A rational approach for the treatment of acute heart failure: current strategies and future options. Curr Opin Cardiol 2004;19:254-63.
23. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005;111:1487-91.
24. Teerlink JR, Massie BM. Nesiritide and worsening of renal function: the emperor's new clothes? Circulation 2005;111:1459-61.
25. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-05.
26. Abraham WT, Adams KF, Fonarow GC, et al, for the ADHERE Scientific Advisory Committee and Investigators, ADHERE Study Group. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the acute decompensated heart failure national registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
27. Topol EJ. Nesiritide: not verified. N Engl J Med 2005;353:113-16.
28. Chang R, Elatre WA, Heywood JT. Effect of nesiritide on length of hospital stay in patients with decompensated heart failure. J Cardiovasc Pharmacol Ther 2004;9:173-7.
29. Lenz TL, Foral PA, Malesker MA, Hunter CB, Hilleman DE. Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure. Pharmacotherapy 2004;24:1137-46.
30. Pettit HE, Carrick AM. Cost-effectiveness of nesiritide in patients treated for congestive heart failure [abstr]. Pharmacotherapy 2003;23:1354.
31. Drummond MF, ed. Methods for the economic evaluation of health care programmes, 2nd ed. Oxford, England: Oxford University Press, 1997.
32. de Lissovoy G, Stier DM, Ciesla G, Munger M, Burger AJ. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am J Cardiol 2003;92:631-3.
33. Hartzema AG, Porta M, Tilson HH, eds. Pharmacoepidemiology: an introduction, 3rd ed. Cincinnati, OH: Harvey Whitney Books, 1998.
34. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Nesiritide submission. Available from http://www.fda.gov/cder/foi/nda/ 2001/20-920_Natrecor_ medr_P4.pdf. Accessed March 9, 2004.
35. Cardinale V, ed. Drug topics red book 2001. Montvale, NJ: Medical Economics Publishing, 2001.
36. Arias E. United States life tables, 2000. National vital statistics reports, December 19, 2002, vol 51, no. 3. Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics, 2002.
37. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998;52:119-26.
38. Braunwald E, Burnett JC Jr, Colucci WS, et al. Panel of cardiology experts provides recommendations to Scios regarding Natrecor. Scios, Inc., Freemont, CA, press release, June 13, 2005. Available from http://www.sciosinc. com/scios/pr_1118721302. Accessed July 6, 2005.